Financhill
Back

Replimune Group Quote, Financials, Valuation and Earnings

Replimune Group Price Quote

$11.40
-0.29 (-2.48%)
(Updated: November 14, 2024 at 5:55 PM ET)

Replimune Group Key Stats

Sell
36
Replimune Group (REPL) is a Sell

Day range:
$11.62 - $12.73
52-week range:
$4.92 - $12.97
Dividend yield:
0%
P/E ratio:
0.00
P/S ratio:
0.00
P/B ratio:
1.95%

Volume:
381.4K
Avg. volume:
460.1K
1-year change:
9.05%
Market cap:
$833.5M
Revenue:
$0
EPS:
$-3.27

How Much Does Replimune Group Make?

Data Unavailable

Is Replimune Group Growing As A Company?

Data Unavailable

Replimune Group Stock Price Performance

  • Did Replimune Group Stock Go Up Last Month?
    Replimune Group share price went up by 1.83% last month
  • Did REPL's Share Price Rise Over The Last Year?
    REPL share price rose by 9.05% over the past 1 year

What Is Replimune Group 52-Week High & Low?

Replimune Group Price To Free Cash Flow

Data Unavailable

Is It Risky To Buy Replimune Group?

  • How Much Debt Does Replimune Group Have?
    Total long term debt quarterly is $0
  • How Much Cash Does Replimune Group Have?
    Cash and short term investments quarterly total is $469.1M
  • What Is Replimune Group’s Book Value Per Share?
    Book value per share is 6.24

Is Replimune Group Cash Flow Positive?

  • What Is REPL Cash Flow From Operations?
    Cash flow from operations (TTM) is -$186M
  • What Is Replimune Group’s Cash Flow From Financing?
    Cash flow from financing (TTM) is $111.8M
  • What Is Replimune Group’s Cash Flow From Investing?
    Cash flow from investing (TTM) is $119.6M

Replimune Group Return On Invested Capital

Data Unavailable

Replimune Group Earnings Date & Stock Price

Replimune Group Competitors

  • Who Are Replimune Group's Competitors?
    Below is a list of companies who compete with Replimune Group or are related in some way:
    • Bristol-Myers Squibb Co (BMY)
    • iBio Inc (IBIO)
    • NovaBay Pharmaceuticals Inc (NBY)
    • Nuvalent Inc (NUVL)
    • Palatin Technologies Inc (PTN)

Replimune Group Dividend Yield

Replimune Group Analyst Estimates

YoY Growth Past Surprise
EPS: 0% 7.69%
Revenue: 0% 0%

Analyst Recommendations

Buy Recommendations: 3
Hold Recommendations: 0
Sell Recommendations: 0
Price Target: 15.75
Upside from Last Price: 34.73%

Major Shareholders

  • How many REPL shares are owned by institutional investors?
    115.7M REPL shares are owned by institutional investors
  • How many REPL shares are owned by insiders?
    5.2M REPL shares are owned by insiders